33 results about "Pleurodesis" patented technology

A localized pleurodesis for lung devices created utilizing a combination of a mechanical component and a chemical component. The chemical component is utilized to create an acute adhesion between the visceral pleural membrane and parietal pleural membrane while the mechanical component is utilized to create a chronic adhesion.

A single-phase surgical procedure is disclosed for creating a pneumostoma to treat chronic obstructive pulmonary disease. In a single-phase technique the pleurodesis is formed at the same time as the pneumostoma and does not require a separate step. The thoracic cavity is accessed to visualize the lung, the pneumostomy catheter is inserted into the lung and then the lung is secured to the channel through the chest wall creating a sealed anastomosis which matures into a pleurodesis after the procedure.

An accelerated two-phase surgical procedure is disclosed for creating a pneumostoma to treat chronic obstructive pulmonary disease. The first phase includes creation of a localized pleurodesis. The localized pleurodesis is created using chemical agents and / or mechanical fasteners to secure the visceral membrane to the pleural membrane. The second phase includes introduction of a surgical instrument into the lung via the pleurodesis to create the pneumostoma. The first and second phases are performed as parts of a single surgical procedure. The formation of a stable pleurodesis is to prevent pneumothorax during the procedure.

A percutaneous single-phase surgical procedure is disclosed for creating a pneumostoma to treat chronic obstructive pulmonary disease. A pneumostomy instrument is introduced percutaneously through the thoracic wall, parietal membrane, visceral membrane and into the parenchymal tissue of the lung. The pneumostomy instrument crosses the pleural cavity between the parietal membrane and visceral membrane there being no pleurodesis between the membranes prior to passage of the pneumostomy instrument. A pneumoplasty device at the distal end of the pneumostomy instrument displaces and engages the parenchymal tissue of the lung and the pneumostomy instrument is used to secure the lung and visceral membrane in contact with the parietal membrane and chest wall. The pneumostomy instrument is left in place while a pneumostoma tract heals and pleurodesis occurs between the pleural membranes surrounding the pneumostomy instrument.

A long term oxygen therapy system having an oxygen supply directly linked with a patient's lung or lungs may be utilized to more efficiently treat hypoxia caused by chronic obstructive pulmonary disease such as emphysema and chronic bronchitis. The system includes an oxygen source, one or more valves and fluid carrying conduits. The fluid carrying conduits link the oxygen source to diseased sites within the patient's lungs. A collateral ventilation bypass trap system directly linked with a patient's lung or lungs may be utilized to increase the expiratory flow from the diseased lung or lungs, thereby treating another aspect of chronic obstructive pulmonary disease. The system includes a trap, a filter / one-way valve and an air carrying conduit. In various embodiments, the system may be intrathoracic, extrathoracic or a combination thereof. In order for the system to be effective, an airtight seal between the parietal and visceral pleurae is required. Chemical pleurodesis is utilized for creating the seal.

A two-phase surgical procedure is disclosed for creating a pneumostoma to treat chronic obstructive pulmonary disease The first phase is a procedure to induce creation of a localized pleurodesis and is preferably performed as an outpatient procedure. The second phase is a procedure to introduce a surgical instrument into the lung via the pleurodesis to create the pneumostoma. An interval of about one of more days between the first and second phases allows the formation of a stable pleurodesis to prevent pneumothorax during the procedure.

System and components for inducing pleurodesis. A tube device is provided that is generally inert in a first state. The device includes a second state that is configured to provide one or both of mechanical and chemical stimulation to induce pleurodesis. Different sheath and tube configurations are provided for the actuatable features of the device.

System and components for inducing pleurodesis or other sclerosis or desired adhesion conditions to treat a patient, while minimizing likelihood of tissue damage from direct application of sclerosis-enhancing materials. A tube device is provided that is configured to elute sclerosis-enhancing material and / or other medicaments via a fenestrated drainage tube. The assembly of tube device with outer (typically drainage) tube may include one or more features configured to enhance delivery of medicament and / or drainage through the same assembly.

System and components for inducing pleurodesis while minimizing likelihood of tissue damage from direct application of pleurodesis-enhancing materials. A tube device is provided that is configured to elute pleurodesis-enhancing material. The device includes one or more features configured to prevent or lessen the likelihood that the pleurodesis-enhancing material comes into direct and concentrated contact with patient tissue when a distal length of the device is disposed indwelling a patient.

Methods and systems for treating pleural disease comprising a providing a low dosage of a sclerosing agent over a period of time. Certain examples include catheter with a sclerosing agent that is inserted into the pleural space. The sclerosing agent is released in a sustained-release manner over a period of time to achieve diffuse pleurodesis of the pleural layers.

The invention provides methods and devices for creating a localized pleurodesis between the thoracic wall and the lung such that a ventilation bypass conduit may be introduced into the lung through the thoracic wall and visceral membrane without causing a pneumothorax. A medical device such as a catheter is used to enter the pleural cavity and deliver a pleurodesis agent to a localized area between the visceral and parietal membranes.

A localized pleurodesis for lung devices created utilizing a combination of a mechanical component and a chemical component. The chemical component is utilized to create an acute adhesion between the visceral pleural membrane and parietal pleural membrane while the mechanical component is utilized to create a chronic adhesion.

A method for administering an active agent to a pleura of a patient includes preparing a composition including a foamable liquid and the active agent, incorporating a gas into the foamable liquid to create a foam containing the active agent, introducing the foam into a pleural cavity of the patient defined by the pleura, and contacting the pleura with the foam. A method of pleurodesis includes introducing a composition into a pleural cavity defined by pleurae of a patient, the composition including a foamable liquid and an active agent capable of causing inflammation and / or adhesion of the pleurae. A composition for treating a pleura of a patient includes a liquid component including a biocompatible composition having a viscosity which increases in response to an increase in temperature, and an active agent capable of causing inflammation and / or adhesion of the pleura.

Methods and systems for treating pleural disease comprising a providing a low dosage of a sclerosing agent over a period of time. Certain examples include catheter with a sclerosing agent that is inserted into the pleural space. The sclerosing agent is released in a sustained-release manner over a period of time to achieve diffuse pleurodesis of the pleural layers.

A ventilation bypass system which alleviates symptoms of chronic obstructive pulmonary disease by allowing air to exit the lung of a patient through the thoracic wall bypassing the natural airways. A pleurodesis is formed between the visceral and parietal membranes surrounding a lung and an opening is made through the thoracic wall into the lung via the pleurodesis. The ventilation bypass system includes a conduit placed through the opening in the thoracic wall into the lung, a flange for securing the conduit to the thoracic wall and preventing over-insertion of the conduit, and a flow control device for controlling flow of material out of the lung.

The invention provides methods and devices for creating a localized pleurodesis between the thoracic wall and the lung such that a ventilation bypass conduit may be introduced into the lung through the thoracic wall and visceral membrane without causing a pneumothorax. A catheter or implantable device delivers the pleurodesis agent to the pleural cavity.

The invention provides methods and devices for creating a localized pleurodesis between the thoracic wall and the lung such that a ventilation bypass conduit may be introduced into the lung through the thoracic wall and visceral membrane without causing a pneumothorax. A medical device such as a catheter is used to enter the pleural cavity and deliver a pleurodesis agent to a localized area between the visceral and parietal membranes.

A method for administering an active agent to a pleura of a patient includes preparing a composition including a foamable liquid and the active agent, incorporating a gas into the foamable liquid to create a foam containing the active agent, introducing the foam into a pleural cavity of the patient defined by the pleura, and contacting the pleura with the foam. A method of pleurodesis includes introducing a composition into a pleural cavity defined by pleurae of a patient, the composition including a foamable liquid and an active agent capable of causing inflammation and / or adhesion of the pleurae. A composition for treating a pleura of a patient includes a liquid component including a biocompatible composition having a viscosity which increases in response to an increase in temperature, and an active agent capable of causing inflammation and / or adhesion of the pleura.

A device, method, and system are provided for treating pleural effusion by administration of a chemical agent through a pleural catheter to achieve pleurodesis. A first embodiment includes a dual barreled syringe to deliver the sclerosing agent; one barrel includes a sclerosing agent, and the other barrel includes a flushing fluid. A kit of the invention comprises a plurality of syringe devices each preloaded with a sclerosing agent matched with a presumptive diagnosis regarding the etiology of the pleural effusion to be treated. A device of the invention includes a handheld, disposable, electronic delivery device with preloaded chambers holding selected medicaments and flushing fluid. Automatic delivery of medicaments is achieved in which a microcontroller of the device controls evacuation of the selected chambers by one or more actuators that communicate with the chambers.

The present invention relates to lipoteichoic acid T for use in treating pleural effusion or pneumothorax. The present invention also relates to the use of lipoteichoic acid T (LTA-T) in the manufacture of a medicament for treating pleural effusion or pneumothorax. The present invention also relates to a kit comprising a pharmaceutical composition comprising lipoteichoic acid T and instructions indicating that the composition is for use as a pleurodesis agent. In addition, the present invention relates to a method of treating pleural effusion or pneumothorax comprising administration of lipoteichoic acid T to a subject.

The innovative aspirator head comprises a tubular handle and a working head part arranged at the front end of the tubular handle, an aspiration channel is formed in the tubular handle, the working head part is an integrally formed flat wedge-shaped aspiration head, and the aspiration channel is communicated with the aspiration channel. At least one suction hole communicated with the suction channel is formed in the stripping working surface; in the whole stripping process, wound surface errhysis is continuously sucked away through the suction holes, it is ensured that the operation view is clear, and the flat wedge-shaped head cannot pierce lung tissue due to the large contact area and the small pressure intensity; meanwhile, the flat wedge-shaped head is easy to insert into a gap, the pure flat blunt end ensures that the front end cannot be punctured, the clinical pain point that a traditional round-head aspirator is easy to poke into or tear fragile lung tissue is effectively solved, stable poking and separation of a fiberboard are achieved by increasing the stress area, and the safety and controllability of an operation are remarkably improved.

System and components for inducing pleurodesis or other sclerosis or desired adhesion conditions to treat a patient, while minimizing likelihood of tissue damage from direct application of sclerosis-enhancing materials. A tube device is provided that is configured to elute sclerosis-enhancing material and / or other medicaments via a fenestrated drainage tube. The assembly of tube device with outer (typically drainage) tube may include one or more features configured to enhance delivery of medicament and / or drainage through the same assembly.

The present invention provides methods of producing pleurodesis in a mammalian subject, comprising administration of a low dosage of a sclerosing agent such as silver or a salt of silver.

A method for administering an active agent to a pleura of a patient includes preparing a composition including a foamable liquid and the active agent, incorporating a gas into the foamable liquid to create a foam containing the active agent, introducing the foam into a pleural cavity of the patient defined by the pleura, and contacting the pleura with the foam. A method of pleurodesis includes introducing a composition into a pleural cavity defined by pleurae of a patient, the composition including a foamable liquid and an active agent capable of causing inflammation and / or adhesion of the pleurae. A composition for treating a pleura of a patient includes a liquid component including a biocompatible composition having a viscosity which increases in response to an increase in temperature, and an active agent capable of causing inflammation and / or adhesion of the pleura.

The present invention provides tissue adhesion using surgical appendages and agents. In general, an implantable appendage can have releasably retained therein one or more agents configured to induce tissue adhesions. The appendage may be configured to be applied to lung tissue using a surgical stapler in conjunction with surgical staples. Pleurodesis can be assisted by delivery of appendages to lung tissue.

A catheter for use in treating pleura diseases, such as pleural effusions and pneumothorax, includes a tip portion that is configured to irritate the pleura when the catheter is inserted in the pleural cavity, thereby initiating mechanical pleurodesis. The tip portion has a substantially rough configuration and may include one or more protrusions that contact the pleura when the catheter is in use, thereby irritating the layers. This irritation causes the creation of fibrous adhesions between the parietal and visceral layers that close off the pleural cavity and prevent further fluid and / or air accumulations that occur as a result of pleural diseases.

Tissue adhesions using surgical adjuncts and medicants are provided. In general, an implantable adjunct can have one or more medicants releasably retained therein that are configured to induce tissueadhesions. The adjunct can be configured to be applied to lung tissue in conjunction with surgical staples using a surgical stapler. Pleurodesis can be encouraged through delivery of the adjunct to the lung tissue.

A catheter for use in treating pleura diseases, such as pleural effusions and pneumothorax, includes a tip portion that is configured to irritate the pleura when the catheter is inserted in the pleural cavity, thereby initiating mechanical pleurodesis. The tip portion has a substantially rough configuration and may include one or more protrusions that contact the pleura when the catheter is in use, thereby irritating the layers. This irritation causes the creation of fibrous adhesions between the parietal and visceral layers that close off the pleural cavity and prevent further fluid and / or air accumulations that occur as a result of pleural diseases.